Environmental and Social Data Sheet

Overview	
Project Name:	BRACCO MEDICAL TECHNOLOGY
Project Number:	2013-0211
Country: Project Description:	Italy Financing of Bracco Group Research and Development activities in the pharma field of contrast media and contrast media injectors.

EIA required: no

Project included in Carbon Footprint Exercise¹: no

(details for projects included are provided in section: "EIB Carbon Footprint Exercise")

Summary of Environmental and Social Assessment, including key issues and overall conclusion and recommendation

The project concerns investments in research and development in the pharma field of contrast media and contrast media injectors that will be carried out in existing facilities without changing their already authorised scope. An Environmental Impact Assessment (EIA) is therefore not required by EIA Directive 2011/92/EU.

The research activities undertaken in the project are aimed to result in creating new diagnostic and therapeutic strategies improving health care quality and thus, the project, if successful, is expected to bring positive social impact.

The project per se does not have any influence on the environment, except limited laboratory waste (biohazard), requesting professional treatment; the project is therefore considered acceptable for the Bank's financing.

Environmental and Social Assessment

Environmental Assessment

.

The project concerns investments in research and development in the pharma field of contrast media and contrast media injectors that will be carried out in existing facilities without changing their already authorised scope. An Environmental Impact Assessment (EIA) is therefore not required by EIA Directive 2011/92/EU.

The project per se does not have any influence on the environment, except laboratory waste (biohazard), requesting professional treatment. The Company is in full compliance with the Global Product Strategy initiative of the European Community Regulation on Chemicals (Reach).

Social Assessment, where applicable

¹ Only projects that meet the scope of the Pilot Exercise, as defined in the EIB draft Carbon Footprint Methodologies, are included, provided estimated emissions exceed the methodology thresholds: above 100,000 tons CO2e/year absolute (gross) or 20,000 tons CO2e/year relative (net) – both increases and savings.

The project, if successful, is expected to lead to significant social benefits resulting from new diagnostic and therapeutic strategies.

Environment and health and safety issues are well integrated into the promoter's management systems. In this respect the promoter has obtained the international ISO 14001 standard and for all of the Group's production plants in Italy.

The promoter has in place specific actions to improve its environmental performance by setting yearly targets in terms of waste management, work environment, use of natural resources, energy and raw material as well as CO₂ emissions. Environmental reports are published early showing the achieved results (www.bracco-sustainability.com).

The parallel certification of the quality management systems in accordance with the ISO 9001 standard enabled Bracco to obtain Certificates of Excellence at its sites in Ceriano Laghetto and Torviscosa.

The promoter's attention to health and safety issues has resulted in the company voluntarily choosing to set up a safety management system certified according to the BS OHSAS 18001:2007 standard at its operational sites in Italy.

For its workers, including researchers taking part in the project, Bracco offers preventive medicine and information programmes via its Italian Diagnostics Centre. It provides also specific training courses regarding health and safety at work.

Year by year, each environmental and safety aspects are analysed and reassessed, highlighting its particular significance and importance on the basis of which improvement objectives and targets are set in accordance with a specific programme.